American Association for Cancer Research
Browse

Supplementary Figure 2 from Chromatin Helicase CHD6 Establishes Proinflammatory Enhancers and Is a Synthetic Lethal Target in FH-Deficient Renal Cell Carcinoma

Download (476.45 kB)
journal contribution
posted on 2025-02-17, 08:20 authored by Juan Jin, Jun Luo, Xiaodong Jin, Kiat Shenq Lim, Yang He, Jiawei Ding, Yan Shen, Yuchen Hou, Hanqing Liu, Xiaoyu Zhu, Jing Zhao, Wenjie Zhou, Hai Huang, Yi Gao, Jun Xiao, Hongchao He, Qunyi Li, Lianxin Liu, Li Chen, Qiang He, Chuanjie Zhang

Supplementary Figure 2. FH deficiency accumulates CHD6 via inactivating Keap1, related to Figure 2&3. A. WB and co-IP analysis indicating no interactions between VHL and CHD6 proteins in WCLs of ACHN cells. B. WB analysis (left) and RT-qPCR (right) indicated the CHD6 protein or mRNA levels in control and VHL-depleted RCC cells. C. Schematic illustration of Keap1 deletion mutants. The binding capacity of Keap1 to CHD6 is indicated with the symbol. D. Western blots showing in vitro ubiquitination assays conducted by incubating the reconstituted Keap1–CUL3–RBX1 E3 ubiquitin ligase complex with E1 and E2 enzymes, ubiquitin and GST-CHD6 at 30 °C for 2 h. E. Aligning ETGE motif sequence in CHD6 and other known Keap1 substrates. F. Western blots of WCLs and co-IP samples of anti-FLAG antibody from ACHN cells transfected with the indicated plasmids and treated with 20 µM MG132 for 8 h. G. Western blots of WCLs from ACHN cells transfected with the indicated plasmids. H. Cells infected with indicated plasmids for 48 h and then treated with 50 μg/mL cycloheximide (CHX) and harvested at different time points. Quantified data were shown. I. Western blot showing the products of in vivo ubiquitination assays from ACHN cells infected with lentivirus expressing FH-specific shRNA or control for 48 h. RT-qPCR analysis (right) showing the Keap1 mRNA levels in indicated samples. J. Western blot showing the products of in vivo ubiquitination assays from UOK-262 cells with or without FH overexpression. RT-qPCR analysis (right) indicating the Keap1 mRNA levels. K. Chemical reaction process showing the generation of D2-DMF. DMAD, dimethyl acetylenedicarboxylate; PPh3, triphenylphosphine; D2O, heavy water (2H2O); THF, tetrahydrofuran. L. FH-WT cells were treated with increased DMF, and fumarate levels were detected. M. WB analysis showing Keap1 expressions in cells treated with or without DMF. N. Decreased fumarate levels were detected in control and FH-overexpressing UOK-262, Caki-2 (D238 H), and Caki-2 (E378K) cells. C1 and C2 indicate the different clones. O. Western blotting assays and Co-IP analysis showing the Keap1-CHD6 interactions in UOK-262 cells. P values were calculated using a two-tailed unpaired t-test (B, I, J, L, N). *p < 0.05, **p < 0.01, and ***p < 0.001. ns, no significance.

Funding

National Natural Science Foundation of China (NSFC)

Natural Science Foundation of Shanghai Municipality (上海市自然科学基金)

History

ARTICLE ABSTRACT

Fumarate hydratase (FH) deficiency causes hereditary leiomyomatosis and renal cell carcinoma (RCC). FH-deficient tumors lack effective therapeutic options. Here, we utilized an epigenetic-focused single-guide RNA library to elucidate potential drug targets in FH-deficient tumors. The screen identified chromodomain helicase DNA-binding protein 6 (CHD6) as an essential regulator of the growth of FH-mutated RCC. Mechanically, FH loss induced fumarate-mediated succinylation and inactivation of KEAP1, blocking subsequent ubiquitin–proteasome degradation of CHD6. Stabilized CHD6 formed a complex with p65 to establish proinflammatory enhancers and thereby regulate NF-κB–mediated transcription. Moreover, CHD6 recruited mSWI/SNF ATPases to maintain chromatin accessibility at CHD6-bound enhancers. The PROTAC degrader of SMARCA2/4 AU-15330 effectively abolished structures of cis-regulatory elements bound by CHD6 and suppressed the growth of FH-mutated, but not FH-intact, RCC in vivo. Collectively, these data indicate that CHD6 is a molecular bridge between FH deficiency and proinflammatory enhancer assembly that endows FH-deficient tumors with epigenetic vulnerabilities.Significance: CHD6 links FH deficiency to aberrant NF-κB activity in renal cell carcinoma, highlighting an epigenetic vulnerability for this rare tumor subtype.